Related Experiment Video
Updated: Jul 28, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Ceftriaxone for the treatment of serious infections
Insights
Ceftriaxone demonstrated efficacy and safety in treating serious pediatric and adult bacterial infections, including pneumonia and sepsis. This cephalosporin antibiotic offers a viable alternative treatment option.
Area of Science:
- Infectious Diseases
- Pharmacology
- Pediatrics
Background:
- Ceftriaxone is a third-generation cephalosporin antibiotic.
- Serious bacterial infections require effective and safe treatment options.
Purpose of the Study:
- To evaluate the efficacy and safety of ceftriaxone in pediatric and young adult patients.
- To assess ceftriaxone as a treatment for various serious bacterial infections.
Main Methods:
- An uncontrolled study was conducted.
- Ceftriaxone was administered intravenously to 30 pediatric and 12 young adult patients.
- Dosages varied based on age and infection type, including central nervous system (CNS) infections.
Main Results:
- All patients achieved clinical cures.
- One case of Pseudomonas pneumonia in a cystic fibrosis patient showed persistent sputum colonization.
- No serious adverse events were reported during the study.
Conclusions:
- Ceftriaxone is effective and safe for treating serious bacterial infections in pediatric and young adult populations.
- Ceftriaxone represents an important alternative therapeutic option, even if not always the first choice.
Abstract:
Ceftriaxone is an investigational cephalosporin with a half-life of five to eight hours. In an uncontrolled study, we evaluated its efficacy and safety in 30 pediatric and 12 young adult patients with serious bacterial infections. This agent was administered to children at a dosage of 50 to 75 mg/kg/day intravenously in two divided doses. Those with CNS infections received 100 mg/kg/day. In adults, the dosage was 1 g either once or twice daily. The diseases we treated included pneumonia (17), sepsis (eight), ventriculoperitoneal shunt infections (three), osteomyelitis (three), brain abscess (two), peritonitis (two), and miscellaneous (seven). Clinical cures were achieved in all cases, although one child with cystic fibrosis and Pseudomonas pneumonia had persistent colonization in his sputum. No serious side effects were observed. Although not the agent of choice for many of these pathogens, ceftriaxone appears to represent an important alternative to therapy.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Acute Pyelonephritis II: Diagnostic Studies and Management
Rocky Mountain Spotted Fever
Inhibitors of Bacterial DNA Synthesis

